Interventional technology developer AngioDynamics reported growth in revenues for the company's third fiscal quarter (end-February 29), although the company's net loss grew as well.
For the period, AngioDynamics reported net sales of $69.8 million, up 6.5% compared with the same period the year before, when the company had revenues of $65.5 million. The company posted a net loss from continuing operations for the most recent quarter of $5.7 million, compared with a net loss from continuing operations of $4.6 million in the third quarter of fiscal 2019.
For the nine-month period year to date, AngioDynamics reported revenues of $205.8 million, an increase of 3.2% compared with sales of $199.5 million in the corresponding quarter of 2019. The firm's net loss from continuing operations was $9.7 million, compared with a net loss from continuing operations of $13.9 million in the same period of 2019.
